Morepen Laboratories' Q4 FY 2025-26 Quarterly Results

Result Summary

• Morepen Laboratories Ltd reported a 1.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 4.8%.
• Its expenses for the quarter were up by 3.8% QoQ and 5.7% YoY.
• The net profit decreased 42.9% QoQ and decreased 22.7% YoY.
• The earnings per share (EPS) of Morepen Laboratories Ltd stood at 0.28 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Morepen Laboratories Ltd is a pharmaceutical company that specializes in the manufacturing and marketing of bulk drugs, formulations, and healthcare products. The company's main focus is on the development and production of active pharmaceutical ingredients (APIs), over-the-counter (OTC) products, diagnostics, and medical devices. Morepen Laboratories has established itself in the pharmaceutical industry with a strong presence in both domestic and international markets. The company is known for its quality products and adherence to stringent manufacturing standards. Recently, Morepen Laboratories has been focusing on expanding its product portfolio and enhancing its manufacturing capabilities to cater to a broader market segment.

Revenue

During the fourth quarter of the fiscal year 2026 (Q4FY26), Morepen Laboratories Ltd reported total income of ₹493.18 crores, representing a quarter-over-quarter (QoQ) growth of 1.1% compared to ₹487.97 crores in Q3FY26. On a year-over-year (YoY) basis, the total income increased by 4.8% from ₹470.46 crores in Q4FY25. This steady increase in revenue indicates a positive trajectory in the company's ability to generate income over both the quarterly and annual periods. The revenue growth reflects the company's efforts in expanding its market reach and possibly increasing its sales volume across various product segments.

Profitability

In Q4FY26, Morepen Laboratories Ltd recorded a profit before tax of ₹23.29 crores, which marks a decrease of 34.2% from the previous quarter's profit before tax of ₹35.42 crores. On a YoY basis, the profit before tax also declined by 9.4% from ₹25.71 crores in Q4FY25. The tax expense for Q4FY26 was ₹7.59 crores, down 4.3% from ₹7.93 crores in Q3FY26, but up 40.6% compared to ₹5.40 crores in Q4FY25. This resulted in a profit after tax of ₹15.70 crores for Q4FY26, which is a significant decrease of 42.9% QoQ and 22.7% YoY. The earnings per share (EPS) for Q4FY26 stood at ₹0.28, down from ₹0.50 in Q3FY26 and ₹0.35 in Q4FY25, reflecting a decline of 44.0% QoQ and 20.0% YoY.

Operating Metrics

The total expenses for Morepen Laboratories Ltd in Q4FY26 were ₹469.90 crores, showing an increase of 3.8% from ₹452.54 crores in Q3FY26 and 5.7% from ₹444.75 crores in Q4FY25. This rise in expenses is notable and indicates a higher cost structure during the quarter. The company's ability to manage its expenses effectively while maintaining or growing revenue is crucial for its operational efficiency. The financial data suggests that while the company has experienced growth in total income, the increase in expenses has impacted profitability metrics such as profit before tax, net profit, and EPS. These operational metrics provide insights into the company's financial management and cost control measures over the analyzed periods.